A dose-escalation study of weekly topotecan, cisplatin, and gemcitabine front-line therapy in patients with inoperable non-small cell lung cancer

Oncologist

Volumn 7, Issue 6, 2002, Pages 509-515

  Guarino, Michael J ^a   Schneider, Charles J ^a   Grubbs, Stephen S ^a   Biggs, David D ^a   Himelstein, Andrew L ^a   Hogaboom, Kurt ^b   Tilak, Samir ^c  

^a HELEN F GRAHAM CANCER CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

^c Virtua Memorial Hospital   (United States)

Author keywords

Cisplatin; Dose escalation; Gemcitabine; Maximum tolerated dose; Non small cell lung cancer; Topotecan

Indexed keywords

CISPLATIN; GEMCITABINE; TOPOTECAN;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FEVER; HEMATOLOGIC DISEASE; HUMAN; INOPERABLE CANCER; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TOPOTECAN; TREATMENT OUTCOME;

EID: 0036918283     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-6-509     Document Type: Article

References (32)

1. Ginsberg RJ, Vokes EE, Raben A. Non-small cell lung cancer: Principles & Practice of Oncology, Fifth Edition. Philadelphia: Lippincott-Raven, 1997:858-911.
2. Scagliotti GV, Novello S, Selvaggi G. Multidrug resistance in non-small cell lung cancer. Ann Oncol 1999;10(suppl 5):S83-S86.
3. Berger W, Elbling L, Hauptmann E et al. Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small cell lung cancer cells. Int J Cancer 1997;73:84-93.
4. Jemal A, Thomas A, Murray T et al. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
5. Ries LAG, Eisner MP, Kosary CL et al. SEER Cancer Statistics Review, 1973-1999. Bethesda, MD: National Cancer Institute. Available at: http://www.seer.cancer.gov/csr/1973-1999. Accessed 2002.
6. Friedel G, Hruska D, Budach W et al. Neoadjuvant chemoradiotherapy of stage III non-small cell lung cancer. Lung Cancer 2000;30:175-185.
7. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. Adopted on May 16, 1997, by the American Society of Clinical Oncology. J Clin Oncol 1997;15:2996-3018.
8. Bonomi PD, Finkelstein DM, Ruckdeschel JC et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: A study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989;7:1602-1613.
9. Bunn Jr PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small-cell lung cancer: A review of the literature and future directions. Clin Cancer Res 1998;4:1087-1100.
10. Bonomi P, Kim K,Fairclough D et al. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000;18:623-631.
11. Langer CJ, Leighton JC, Comis RL et al. Paclitaxel and carboplatin in combination in the treatment of advanced non small-cell lung cancer: A phase II toxicity, response, and survival analysis. J Clin Oncol 1995;13:1860-1870.
12. Schiller JH, Harrington D, Sandler A et al. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000;19:1a.
13. Crino L, Scagliotti G, Marangolo M et al. Cisplatin-gemcitabine combination in advanced non-small cell lung cancer: A phase II study. J Clin Oncol 1997;15:297-303.
14. Wall JG, Burris 3rd HA, Von Hoff DD et al. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs 1992;3:337-345.
15. Saltz L, Sirott M, Young C et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 1993;85:1499-1507.
16. Rowinsky EK, Grochow LB, Hendricks CB et al. Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 1992;10:647-656.
17. Verweij J, Lund B, Beijnen J et al. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 1993;4:673-678.
18. Perez-Soler R, Fossella FV, Glisson BS et al. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 1996;14:503-513.
19. Perez-Soler R, Khuri F, Pisters KM et al. Phase II study of topotecan in patients with squamous carcinoma of the lung previously untreated with chemotherapy. Proc Am Soc Clin Oncol 1997;16:450a.
20. Kindler HL, Kris MG, Smith IE et al. Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small cell lung cancer. Am J Clin Oncol 1998;21:438-441.
21. White SC, Cheeseman S, Thatcher N et al. Phase II study of oral topotecan in advanced non-small cell lung cancer. Clin Cancer Res 2000;6:868-873.
22. Gatzemeier U, von Pawel J, Gottfried M et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer. J Clin Oncol 2000;18:3390-3399.
23. Manegold C, Zatloukal P, Krejcy K et al. Gemcitabine in non-small cell lung cancer (NSCLC). Invest New Drugs 2000;18:29-42.
24. ten Bokkel Huinink WW, Bergman B, Chemaissani A et al. Single-agent gemcitabine: An active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer. Lung Cancer 1999;26:85-94.
25. Rowinsky EK, Kaufmann SH, Baker SD et al. Sequences of topotecan and cisplatin: Phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 1996;14:3074-3084.
26. Cheng MF, Chatterjee S, Berger NA. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res 1994;6:269-279.
27. Hoskins P, Eisenhauer E, Beare S et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1998;16:2233-2237.
28. Rose PG, Gordon NH, Fusco N et al. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. Gynecol Oncol 2000;78:228-234.
29. Homesley HD, Hall DJ, Martin DA et al. Weekly bolus topotecan toxicity and dose response trial in second or third line therapy of epithelial ovarian carcinoma. Proc Am Soc Clin Oncol 2000;19:395a.
30. Frasci G, Nicolella G, Comella P et al. A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: A phase II study. Br J Cancer 2001;84:1166-1171.
31. Schiller JH. Current standards of care in small-cell and non-small cell lung cancer. Oncology 2001;61(suppl 1):3-13.
32. Schiller JH. Future role of topotecan in the treatment of lung cancer. Oncology 2001;61(suppl 1):55-59.